Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
1969
|
| gptkbp:ATCCode |
gptkb:N06AA12
|
| gptkbp:brand |
gptkb:Adapin
|
| gptkbp:contraindication |
urinary retention
narrow angle glaucoma |
| gptkbp:drugClass |
antidepressant
|
| gptkbp:eliminationHalfLife |
8-24 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
capsule
oral solution |
| gptkbp:genericName |
gptkb:doxepin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sinequan
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:mechanismOfAction |
inhibits reuptake of norepinephrine and serotonin
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
constipation
blurred vision weight gain drowsiness dry mouth |
| gptkbp:usedFor |
gptkb:depression
anxiety |
| gptkbp:bfsParent |
gptkb:doxepin
gptkb:Doxepin |
| gptkbp:bfsLayer |
7
|